Proposed Data Collection Submitted for Public Comment and Recommendations, 38151-38153 [2024-09857]
Download as PDF
<![CDATA[
38151
Federal Register / Vol. 89, No. 89 / Tuesday, May 7, 2024 / Notices
effectiveness of TA efforts by
streamlining and centralizing the
provision of overdose surveillance and
prevention TA. TA to OD2A recipients
is divided into four different levels with
multiple modes of TA delivery and
involves a wide range of TA providers
appropriate resources to support their
needs.
CDC requests OMB approval for an
estimated 388 annual burden hours.
There is no cost to respondents other
than their time to participate.
including CDC staff, internal and
external subject matter experts (SMEs)
and program partners as well as Tanaq
and ICF staff. The four TA levels below
are used to direct the process for
engaging stakeholders to support
program recipients and triage
ESTIMATED ANNUALIZED BURDEN HOURS
Total burden
(in hours)
Form name
OD2A (OD2A in States and OD2A:
LOCAL) Recipients.
Individual TA Feedback Form ..........
618
2
5/60
103
Universal TA Feedback Form ..........
Implementation Feedback Survey ...
Annual Technical Assistance Survey
Email invitation for Annual ...............
Focus Group Session Script ............
Focus Groups Email invitation .........
617
18
162
900
100
600
2
1
1
........................
1
1
5/60
15/60
10/60
2/60
1
2/60
103
4.5
27
30
100
20
...........................................................
........................
........................
........................
388
Total ...........................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–09843 Filed 5–6–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–24FI; Docket No. CDC–2024–
0036]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Comprehensive Evaluations of the
Division for Heart Disease and Stroke
Prevention Programs (WISEWOMAN,
National CVH Program, Innovative CVH
Program). The purpose of the data
collection is to evaluate the
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Type of respondents
VerDate Sep<11>2014
15:55 May 06, 2024
Jkt 262001
implementation of evidence-based
strategies within these programs,
measure their impact on cardiovascular
disease (CVD) prevention and
management, and to identify strategies
that are most effective in reaching
populations disproportionately affected
by CVD.
DATES: CDC must receive written
comments on or before July 8, 2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0036 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
PO 00000
Frm 00134
Fmt 4703
Sfmt 4703
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
E:\FR\FM\07MYN1.SGM
07MYN1
38152
Federal Register / Vol. 89, No. 89 / Tuesday, May 7, 2024 / Notices
5. Assess information collection costs.
Proposed Project
Comprehensive Evaluations of the
Division for Heart Disease and Stroke
Prevention Programs (WISEWOMAN,
National CVH Program, Innovative CVH
Program)—New—National Center for
Chronic Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
khammond on DSKJM1Z7X2PROD with NOTICES
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) Division for Heart
Disease and Stroke Prevention (DHDSP)
are submitting this new three-year
information collection request (ICR) for
an evaluation of three recently launched
cooperative agreements: Well-Integrated
Screening of Women Across the Nation
(WISEWOMAN), The National
Cardiovascular Health Program (The
National CVH Program), and The
Innovative Cardiovascular Health
Program (The Innovative CVH Program).
The WISEWOMAN program supports
the early detection and treatment of
hypertension in low-income, uninsured,
and underinsured participants, ages 35–
64. The National CVH Program
implements evidence-based strategies to
manage CVD in populations impacted
by the high prevalence of CVD,
exacerbated by health inequities and
disparities, emphasizing hypertension
and high cholesterol control among
adults aged 18–85. The Innovative CVH
Program focuses on implementing
innovative evidence-based strategies to
assess and address the health disparities
and inequities in communities at
highest risk (defined as census tracts
with a crude hypertension prevalence of
53% or higher), where there is a
particular need for equity-focused
health system interventions to prevent,
detect, control, and manage
hypertension and high cholesterol.
These three programs build upon CDC’s
previous work to identify promising
CVD prevention and management
practices and fund various
organizations, including State and
County governments, American Indian
or Alaska Native tribal governments,
non-government organizations,
institutions of higher education, to
implement evidence-based strategies in
their jurisdictions. Since the programs
are a substantial investment of federal
funds, comprehensive evaluations are
important to demonstrate the types of
interventions being implemented and
what is being accomplished using these
funds.
The comprehensive evaluation of
these programs includes process and
outcome evaluations, and a crossprogram analysis to assess the unique
contributions of each program towards
evidence-based strategies, health equity
advancement, and health system
transformation over the five program
years. The evaluation aims to describe
the implementation of the programs,
assess the extent to which short-term,
intermediate, and long-term outcomes
have been met, and estimate the costs
involved in implementing the programs.
The comprehensive evaluation is
designed to complement the evaluations
already being conducted by program
recipients. The data collection focuses
on obtaining qualitative and cost
information at the organizational and
community levels about strategy
implementation, facilitators and
barriers, and other contextual
information that affects program
implementation and participant
outcomes. Data collection activities of
Form name
Recipients .........................................
Evaluability Assessment Nomination
Form_NCHP_ICHP.
Evaluability Assessment Nomination
Form_WW.
Eval Assessment CCL Recipient
Interview Guide NCHP_ICHP.
Eval Assessment CQM Recipient
Interview Guide NCHP_ICHP.
Eval Assessment TBC Recipient
Interview Guide NCHP_ICHP.
Eval Assessment CCL Recipient
Interview Guide WW.
Eval Assessment CQM Recipient
Interview Guide WW.
Eval Assessment TBC Recipient
Interview Guide WW.
Ex Assessment CCL Recipient
Interview Guide_WW.
VerDate Sep<11>2014
15:55 May 06, 2024
Jkt 262001
PO 00000
Frm 00135
Number of
responses per
respondent
Number of
respondents
Type of respondents
Fmt 4703
Sfmt 4703
the comprehensive evaluation include
qualitative interviews for evaluability
assessments, exploratory assessments,
and cost data collected for a cost study.
During the qualitative data collection,
semi-structured interviews will be
conducted with recipients, their
partnering sites, and Learning
Collaborative members, providing a
multifaceted view of the program’s
implementation and outcomes. Cost
data will be used to estimate the
implementation costs and value of
resources invested by program
recipients and their partners. Cost data
will be collected through a spreadsheetbased cost inventory tool, key informant
interviews, and document reviews.
There are no costs to respondents except
their time. Data collection tools are
crafted to ensure relevance and capture
essential information needed to evaluate
the effectiveness and impact of the
program strategies, while minimizing
respondent burden.
The findings from the data collection
will provide tailored, action-oriented,
and timely recommendations for
program improvement throughout the
program period. Findings will foster
documentation and sharing of lessons
learned, contribute to the evidence base,
and support replication and scaling of
promising program strategies. Without
collection of evaluative data, CDC will
not be able to capture critical
information needed to continuously
improve programmatic efforts and
clearly demonstrate the responsible use
of federal funds.
CDC requests OMB approval for an
estimated 2,054 annual burden hours.
There is no cost to respondents other
than their time to participate.
Estimated Annualized Burden Hours:
Average
burden per
response
(in hours)
Total burden
(in hours)
72
1
0.5
36
35
1
0.5
17.5
18
1
1.5
27
18
1
1.5
27
18
1
1.5
27
8
1
1.5
12
8
1
1.5
12
8
1
1.5
12
4
1
1.5
6
E:\FR\FM\07MYN1.SGM
07MYN1
38153
Federal Register / Vol. 89, No. 89 / Tuesday, May 7, 2024 / Notices
Type of respondents
Learning Collaborative ......................
Totals .........................................
Ex Assessment CQM Recipient
Interview Guide_WW.
Ex Assessment TBC Recipient Partner Interview Guide_WW.
Ex Assessment CCL Recipient
Interview Guide NCHP_ICHP.
Ex Assessment CQM Recipient
Interview Guide NCHP_ICHP.
Ex Assessment TBC Recipient
Interview Guide NCHP_ICHP.
Cost Study Interview Guide_Recipient.
Comprehensive Evaluation Resource Use and Cost Inventory
Tool_Recipient.
Eval Assessment CCL Partner Interview Guide NCHP_ICHP.
Eval Assessment CQM Partner
Interview Guide NCHP_ICHP.
Eval Assessment TBC Partner Interview Guide NCHP_ICHP.
Eval Assessment CCL Partner Interview Guide WW.
Eval Assessment CQM Partner
Interview Guide WW.
Eval Assessment TBC Partner Interview Guide WW.
Ex Assessment CCL Partner Interview Guide_WW.
Ex Assessment CQM Partner Interview Guide_WW.
Ex Assessment TBC Partner Interview Guide_WW.
Ex Assessment CCL Partner Interview Guide NCHP_ICHP.
Ex Assessment CQM Partner Interview Guide NCHP_ICHP.
Ex Assessment TBC Partner Interview Guide NCHP_ICHP.
Comprehensive Evaluation Resource Use and Cost Inventory
Tool_Partner.
Cost Study Interview Guide_Partner
Eval Assessment LC Interview
Guide_NCHP_ICHP.
Ex Assessment LC Interview Guide
NCHP_ICHP.
...........................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
1
1.5
6
4
1
1.5
6
9
1
1.5
13.5
9
1
1.5
13.5
9
1
1.5
13.5
165
1
1
165
110
1
2.5
275
18
1
1.5
27
18
1
1.5
27
18
1
1.5
27
8
1
1.5
12
8
1
1.5
12
8
1
1.5
12
4
1
1.5
6
4
1
1.5
6
4
1
1.5
6
9
1
1.5
13.5
9
1
1.5
13.5
9
1
1.5
13.5
330
1
2.5
825
330
36
1
1
1
1
330
36
18
1
1
18
........................
........................
........................
2054
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-24–24EZ; Docket No. CDC–2024–
0031]
khammond on DSKJM1Z7X2PROD with NOTICES
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
VerDate Sep<11>2014
15:55 May 06, 2024
Jkt 262001
PO 00000
Frm 00136
Fmt 4703
Total burden
(in hours)
4
[FR Doc. 2024–09857 Filed 5–6–24; 8:45 am]
BILLING CODE 4163–18–P
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Form name
Sfmt 4703
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Assessing
Sexual and Gender Minority (SGM)
Occupational Well-Being from The
PRIDE Study. This project aims to
describe the SGM workforce population,
their health and well-being experiences,
SUMMARY:
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 89, Number 89 (Tuesday, May 7, 2024)]
[Notices]
[Pages 38151-38153]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24FI; Docket No. CDC-2024-0036]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled Comprehensive Evaluations of the
Division for Heart Disease and Stroke Prevention Programs (WISEWOMAN,
National CVH Program, Innovative CVH Program). The purpose of the data
collection is to evaluate the implementation of evidence-based
strategies within these programs, measure their impact on
cardiovascular disease (CVD) prevention and management, and to identify
strategies that are most effective in reaching populations
disproportionately affected by CVD.
DATES: CDC must receive written comments on or before July 8, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0036 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
[[Page 38152]]
5. Assess information collection costs.
Proposed Project
Comprehensive Evaluations of the Division for Heart Disease and
Stroke Prevention Programs (WISEWOMAN, National CVH Program, Innovative
CVH Program)--New--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) Division for
Heart Disease and Stroke Prevention (DHDSP) are submitting this new
three-year information collection request (ICR) for an evaluation of
three recently launched cooperative agreements: Well-Integrated
Screening of Women Across the Nation (WISEWOMAN), The National
Cardiovascular Health Program (The National CVH Program), and The
Innovative Cardiovascular Health Program (The Innovative CVH Program).
The WISEWOMAN program supports the early detection and treatment of
hypertension in low-income, uninsured, and underinsured participants,
ages 35-64. The National CVH Program implements evidence-based
strategies to manage CVD in populations impacted by the high prevalence
of CVD, exacerbated by health inequities and disparities, emphasizing
hypertension and high cholesterol control among adults aged 18-85. The
Innovative CVH Program focuses on implementing innovative evidence-
based strategies to assess and address the health disparities and
inequities in communities at highest risk (defined as census tracts
with a crude hypertension prevalence of 53% or higher), where there is
a particular need for equity-focused health system interventions to
prevent, detect, control, and manage hypertension and high cholesterol.
These three programs build upon CDC's previous work to identify
promising CVD prevention and management practices and fund various
organizations, including State and County governments, American Indian
or Alaska Native tribal governments, non-government organizations,
institutions of higher education, to implement evidence-based
strategies in their jurisdictions. Since the programs are a substantial
investment of federal funds, comprehensive evaluations are important to
demonstrate the types of interventions being implemented and what is
being accomplished using these funds.
The comprehensive evaluation of these programs includes process and
outcome evaluations, and a cross-program analysis to assess the unique
contributions of each program towards evidence-based strategies, health
equity advancement, and health system transformation over the five
program years. The evaluation aims to describe the implementation of
the programs, assess the extent to which short-term, intermediate, and
long-term outcomes have been met, and estimate the costs involved in
implementing the programs. The comprehensive evaluation is designed to
complement the evaluations already being conducted by program
recipients. The data collection focuses on obtaining qualitative and
cost information at the organizational and community levels about
strategy implementation, facilitators and barriers, and other
contextual information that affects program implementation and
participant outcomes. Data collection activities of the comprehensive
evaluation include qualitative interviews for evaluability assessments,
exploratory assessments, and cost data collected for a cost study.
During the qualitative data collection, semi-structured interviews will
be conducted with recipients, their partnering sites, and Learning
Collaborative members, providing a multifaceted view of the program's
implementation and outcomes. Cost data will be used to estimate the
implementation costs and value of resources invested by program
recipients and their partners. Cost data will be collected through a
spreadsheet-based cost inventory tool, key informant interviews, and
document reviews. There are no costs to respondents except their time.
Data collection tools are crafted to ensure relevance and capture
essential information needed to evaluate the effectiveness and impact
of the program strategies, while minimizing respondent burden.
The findings from the data collection will provide tailored,
action-oriented, and timely recommendations for program improvement
throughout the program period. Findings will foster documentation and
sharing of lessons learned, contribute to the evidence base, and
support replication and scaling of promising program strategies.
Without collection of evaluative data, CDC will not be able to capture
critical information needed to continuously improve programmatic
efforts and clearly demonstrate the responsible use of federal funds.
CDC requests OMB approval for an estimated 2,054 annual burden
hours. There is no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours:
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Recipients.................... Evaluability 72 1 0.5 36
Assessment
Nomination
Form_NCHP_ICHP.
Evaluability 35 1 0.5 17.5
Assessment
Nomination
Form_WW.
Eval Assessment 18 1 1.5 27
CCL Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
CQM Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
TBC Recipient
Interview Guide
NCHP_ICHP.
Eval Assessment 8 1 1.5 12
CCL Recipient
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
CQM Recipient
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
TBC Recipient
Interview Guide
WW.
Ex Assessment 4 1 1.5 6
CCL Recipient
Interview
Guide_WW.
[[Page 38153]]
Ex Assessment 4 1 1.5 6
CQM Recipient
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
TBC Recipient
Partner
Interview
Guide_WW.
Ex Assessment 9 1 1.5 13.5
CCL Recipient
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
CQM Recipient
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
TBC Recipient
Interview Guide
NCHP_ICHP.
Cost Study 165 1 1 165
Interview
Guide_Recipient.
Comprehensive 110 1 2.5 275
Evaluation
Resource Use
and Cost
Inventory
Tool_Recipient.
Eval Assessment 18 1 1.5 27
CCL Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
CQM Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 18 1 1.5 27
TBC Partner
Interview Guide
NCHP_ICHP.
Eval Assessment 8 1 1.5 12
CCL Partner
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
CQM Partner
Interview Guide
WW.
Eval Assessment 8 1 1.5 12
TBC Partner
Interview Guide
WW.
Ex Assessment 4 1 1.5 6
CCL Partner
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
CQM Partner
Interview
Guide_WW.
Ex Assessment 4 1 1.5 6
TBC Partner
Interview
Guide_WW.
Ex Assessment 9 1 1.5 13.5
CCL Partner
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
CQM Partner
Interview Guide
NCHP_ICHP.
Ex Assessment 9 1 1.5 13.5
TBC Partner
Interview Guide
NCHP_ICHP.
Comprehensive 330 1 2.5 825
Evaluation
Resource Use
and Cost
Inventory
Tool_Partner.
Cost Study 330 1 1 330
Interview
Guide_Partner.
Learning Collaborative........ Eval Assessment 36 1 1 36
LC Interview
Guide_NCHP_ICHP.
Ex Assessment LC 18 1 1 18
Interview Guide
NCHP_ICHP.
---------------------------------------------------------------
Totals.................... ................ .............. .............. .............. 2054
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-09857 Filed 5-6-24; 8:45 am]
BILLING CODE 4163-18-P
